EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MET exon 14 skipping mutation is a hepatocyte growth factor ( HGF )‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice

Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie-José Truong, Valérie Grégoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean-Pascal Meneboo und 13 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Marie Fernandes und 24 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to The…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small‐cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET‐tyrosine kinase inhibitors (TKIs), underlying the need to understand the mechanism of METex14 oncogenicity and sensitivity to TKIs. Whether METex14 is a driver mutation and whether it requires hepatocyte growth factor (HGF) for its oncogenicity in a range of in vitro functions and in vivo has not been fully elucidated from previous preclinical models. Using CRISPR/Cas9, we developed a METex14/WT isogenic model in nontransformed human lung cells and report that the METex14 single alteration was sufficient to drive MET‐dependent in vitro anchorage‐independent survival and motility and in vivo tumorigenesis, sensitising tumours to MET‐TKIs. However, we also show that human HGF (hHGF) is required, as demonstrated in vivo using a humanised HGF knock‐in strain of mice and further detected in tumour cells of METex14 NSCLC patient samples. Our results also suggest that METex14 oncogenicity is not a consequence of an escape from degradation in our cell model. Thus, we developed a valuable model for preclinical studies and present results that have potential clinical implication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansExonsHepatocyte Growth FactorMutationProtein Kinase InhibitorsProto-Oncogene Proteins c-metAnimalsMice

Stichwörter der Autor:innen

hepatocyte growth factorlung cancerpreclinical modelstargeted therapiestranscriptomictyrosine kinase receptor

Substanzen

Hepatocyte Growth FactorHGF protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metHGF protein, mouse

Autor:innen und Institutionen

  • Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, France.
  • Barts Cancer Institute, Queen Mary University of London, UK.
  • Univ Lille, Department of Pathology, CHU Lille, France.
  • Univ. Lille, Molecular Biology, Hormonology Metabolism Nutrition Oncology, CHU Lille, France.
  • Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.
  • OCTIMET Oncology NV, Beerse, Belgium.

ORCID-Profile: Zoulika Kherrouche

Förderung

  • Wellcome Trust
  • Medical Research Council
  • Biotechnology and Biological Sciences Research Council
  • Agence Nationale de la Recherche
  • Barts Charity
  • Institut National Du Cancer
  • Rosetrees Trust

Zitieren

APA

Fernandes, M., Hoggard, B., Jamme, P., Paget, S., Truong, M. J., Grégoire, V., Vinchent, A., Descarpentries, C., Morabito, A., Stanislovas, J., Farage, E., Meneboo, J. P., Sebda, S., Bouchekioua-Bouzaghou, K., Nollet, M., Humez, S., Perera, T., Fromme, P., Grumolato, L., …, & Kherrouche, Z. (2023). MET exon 14 skipping mutation is a hepatocyte growth factor ( HGF )‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice. Molecular Oncology. https://doi.org/10.1002/1878-0261.13397

Vancouver

Fernandes M, Hoggard B, Jamme P, Paget S, Truong MJ, Grégoire V, et al. MET exon 14 skipping mutation is a hepatocyte growth factor ( HGF )‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice. Molecular Oncology. 2023. doi:10.1002/1878-0261.13397

BibTeX
@article{Fernandes2023,
  author = {Fernandes, Marie and Hoggard, Brynna and Jamme, Philippe and Paget, Sonia and Truong, Marie-José and Grégoire, Valérie and Vinchent, Audrey and Descarpentries, Clotilde and Morabito, Angela and Stanislovas, Justas and Farage, Enoir and Meneboo, Jean-Pascal and Sebda, Shéhérazade and Bouchekioua-Bouzaghou, Katia and Nollet, Marie and Humez, Sarah and Perera, Timothy and Fromme, Paul and Grumolato, Luca and Figeac, Martin and Copin, Marie-Christine and Tulasne, David and Cortot, Alexis B and Kermorgant, Stéphanie and Kherrouche, Zoulika},
  title = {MET exon 14 skipping mutation is a hepatocyte growth factor ( HGF )‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13397}
}
Kostenlos starten →